The global COVID-19 pandemic has led to unprecedented levels of educational disruption through school closures. The resumption of in-person learning has proven to be controversial, as officials and communities weigh the risks of potential transmission of SARS-CoV-2 in schools against the benefits of in-person learning.
A large, national, multicentre prospective cohort study of hospital healthcare workers in the UK (The SARS-CoV-2 Immunity and Reinfection Evaluation, SIREN) reports, in an interim analysis published in The Lancet, that participants who previously had SARS-CoV-2 antibodies had an 84% lower risk of (re)infection.
Many respiratory viral infections, such as the seasonal flu, target the two most immune-vulnerable populations, younger children and seniors.
Antibody levels stay elevated throughout six months after the second dose of the Moderna COVID-19 vaccine
The Moderna mRNA-1273 vaccine was previously shown to be 94.1% efficacious at preventing COVID-19 illness in a phase 3 trial of 30,420 volunteers.
The original Wuhan strain of SARS-CoV-2 has been evolving constantly since the onset of the COVID-19 pandemic.